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Upregulation of the plasma membrane receptor IL1RAP in Acute Myeloid Leukemia (AML) has been 
reported but its role in the context of the leukemic bone marrow niche is unclear. Here, we studied the 
signaling events downstream of IL1RAP in relation to leukemogenesis and normal hematopoiesis. High 
IL1RAP expression was associated with a leukemic GMP-like state, and knockdown of IL1RAP in AML 
reduced colony-forming capacity. Stimulation with IL1β resulted in the induction of multiple chemokines 
and an inflammatory secretome via the p38 MAPK and NFκB signaling pathways in IL1RAP-expressing 
AML cells, but IL1β-induced signaling was dispensable for AML cell proliferation and NFκB-driven 
survival. IL1RAP was also expressed in stromal cells where IL1β induced expression of inflammatory 
chemokines and cytokines as well. Intriguingly, the IL1β-induced inflammatory secretome of IL1RAP-
expressing AML cells grown on a stromal layer of mesenchymal stem cells affected normal 
hematopoiesis including hematopoietic stem/progenitor cells while AML cell proliferation was not 
affected. The addition of Anakinra, an FDA-approved IL1 receptor antagonist, could reverse this effect. 
Therefore, blocking the IL1-IL1RAP signaling axis might be a good therapeutic approach to reduce 
inflammation in the bone marrow niche and thereby promote normal hematopoietic recovery over AML 




The fate of both AML and normal hematopoietic stem cells (HSCs) is critically dependent on 
interactions with the bone marrow (BM) niche.
1-4
 Recent data has also suggested that malignant cells can 
remodel the BM microenvironment into a leukemic BM niche favoring leukemogenesis over normal 
hematopoiesis.
4-6
 Plasma membrane (PM) proteins are first in line to respond to signals that arise from 
the BM niche. One of these PM proteins, Interleukin-1 receptor accessory protein (IL1RAP), is specifically 
upregulated in stem/progenitor cells from chronic myeloid leukemia (CML) and AML patients but not on 
normal CD34
+
 hematopoietic stem/progenitor cells (HSPCs).
7-10
 This has led to several studies that 
investigated the targetability of IL1RAP as treatment strategy of chronic myeloid leukemia (CML) and 
acute myeloid leukemia (AML),
9,11-13
 but little is known regarding the cell-intrinsic role of IL1RAP in AML 
stem/progenitor cells. In addition, the canonical Interleukin-1 (IL1)-IL1RAP signaling axis in AML with 
respect to the leukemic BM niche has not been studied extensively. 
 The IL1 family is part of the innate immunity that regulates local inflammatory responses, and its 
dysregulation may lead to autoinflammatory diseases often caused by excessive IL1β production.14 The 
IL1 family consists of 7 ligands including IL1α, IL1β, IL18, IL33, IL36α, β and γ that can bind different IL1 
receptors whereby the majority forms a dimer with the IL1RAP co-receptor.
15
 Activation of the IL1 
receptor complex activates the MyD88/IRAK1/IRAK4/TRAF6/TAK1 signaling pathway, which in turn 
results in activation of NFκB and mitogen-activated protein kinases (MAPK), including p38.16 Many of 
proteins in this pathway are often upregulated in Myelodysplastic Syndromes (MDS) and AML, which 
suggests an important role for this pathway in leukemogenesis.
17-19
 The IL1 signaling route can induce a 
variety of inflammatory cytokines and chemokines, which has been shown to be an important factor for 
development and maintenance of MDS.
20






 Here, we studied the IL1–IL1RAP signaling axis in primary AML patients in the context of the BM 




Extensive details on the methods used can be found in the online supplement. 
 
Primary samples 
Neonatal cord blood (CB), mobilized peripheral blood stem cells (PBSCs), normal bone marrow (NBM), 
mesenchymal stromal cells (MSCs), MDS, and AML patient material was obtained as described in the 
Supplemental Methods. All healthy individuals and AML patients gave an informed consent in 
accordance with the Declaration of Helsinki at the University Medical Centre Groningen (UMCG) and 
Martini Hospital Groningen, the Netherlands. All protocols were approved by the Medical Ethical 








 or AML CD34
+
 cells were performed in 
Gartner’s medium with the addition of 20ng/mL granulocyte colony-stimulating factor (G-CSF), N-plate 
and IL3. Inhibition of the IL1-signaling pathway was established by the addition of 500ng/mL Anakinra 
(Swedish Orphan Biovitrum BVBA). In case of triple co-cultures, CB CD34
+
 cells were transduced with 
pLKO eGFP to distinguish them from AML cells. Co-cultures were grown at 37˚C and 5% CO2 and demi-
populated regularly, replacing 50-80% of the volume with fresh or conditioned Gartner’s medium. 




Colony-forming-cell (CFC) assay 
The colony-forming capacity of CB CD34
+
 cells was evaluated in methylcellulose (1600µL) mixed with CM 
(900µL) from MSC-AML co-cultures treated for 7 days with or without IL1β and Anakinra. 
 
Lentiviral transfection 
For knockdown of IL1RAP, cells were transduced with a pLKO eGFP construct, containing short hairpins 
against IL1RAP sh1: 5’-TGGCCTTACTCTGATCTGGTATTGGACTA-3’, sh2: 5’-
CGGGCATTAATTGATTTCCTACTATATTC-3’,
10
 or scrambled control 5’-TTCTCCGAACGTGTCACGTT-3’. 
 
Results 
IL1RAP is upregulated in AML patients and correlates with a leukemic-GMP (L-GMP) signature.  
IL1RAP expression was evaluated in NBM CD34
+
 cells (n=11) and blasts of AML, Acute 






 in case of NPM1 mutant AMLs 
with CD34 expression <1%). De novo AML patients (n=110), patients that developed an AML from an 
MDS (s-AML) (n=27), APL patients (n=4), and MDS/MDS-Excess Blasts (MDS-EB) patients (n=13), all 
showed heterogeneous but on average significantly upregulated expression of IL1RAP (Supplemental 
Figure 1A-B). Immunofluorescent staining showed clear IL1RAP expression on the PM in AML cells 
representing different genetic subtypes with high IL1RAP expression (Figure 1A).  
For 42 AML patients, quantitative proteome data was generated previously
7
 and we evaluated 
cellular processes that were enriched in patients with either high or low IL1RAP expression. For 31 of 
these patients IL1RAP expression was also measured by flow cytometry independently and a significant 
correlation with our quantitative proteome data was observed (Supplemental Figure 1C). Gene ontology 
(GO) and gene set enrichment analysis (GSEA) was performed on a ranked list based on Pearson 
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correlations of IL1RAP protein expression with the complete quantitative proteome showed that high 
expression of IL1RAP was associated with the terms “mitochondrial translation elongation and 
termination”, “energy production via oxidative phosphorylation” and a “L-GMP signature”, whereas AML 
patients with low IL1RAP expression were associated with “regulation of RNA metabolic processes”, 
“gene expression” and a glycolysis-enriched HSC-like signature (Figure 1B-C). While IL1A and IL1B were 
expressed by AML cells at varying levels, no correlations were seen with IL1RAP expression, neither in 
our quantitative proteome data nor in various published transcriptome datasets (data not shown).
24,25
 
Neither did we find positive correlations of IL1RAP
high
-expressing AMLs with RELA, encoding the NFκB 
transcription factor, MyD88, IRAK1, and TRAF6, all associated with the IL1-IL1RAP downstream pathway 
(data not shown). 
 
IL1-induced IL1RAP signaling is associated with an inflammatory secretome. 
Data generated in previous studies comparing gene expression profiles of primary AML and NBM 
CD34
+
 cells suggested that the IL1RAP pathway might be actively used in many AML patients since 
components of the IL1RAP-TAK1 signaling pathway were significantly upregulated in AML CD34
+
 cells 
while negative feedback proteins such as IL1R2, IL1RN and MARCH8 were significantly downregulated 
(Supplemental Figure 2A).
24
 To investigate the repertoire of targets downstream of the IL1-IL1RAP axis 
we performed genome-wide transcriptome studies in CD34
+
 of AML#1 (for details of all AMLs used in this 
study, see Supplemental Table 1), THP1, and K562 cells that were stimulated with IL1β for 1 hr 
(Supplemental Table 2). While the IL1RAP receptor can be activated by multiple different cytokines 
including IL1α, IL1β, IL33, and IL36 depending on its co-receptor IL1R1, IL1RL1 or IL1RL2, and although 
e.g. IL33 has also recently been shown to impact on HSCs
26
, we initially focused on IL1β in our studies 
since the IL1R1 receptor appeared to be the highest expressed in some AML subsets (data not shown) 
and given its potential role in inflammation
27
, which we wanted to investigate in more detail.  
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AML#1 and THP1 cells both had a high IL1RAP expression whereas K562 showed partial IL1RAP 
expression (Supplemental Figure 2B). We identified 299 genes that were >2-fold upregulated in at least 2 
groups and 32 genes that were >2-fold upregulated in all three groups (Figure 2A). GO analysis on the 
combination of these genes (331) showed enrichment for genes associated with chemokine signaling, 
inflammation, response to IL1 and an anti-apoptotic signature (Figure 2B). In addition, GSEA on a ranked 
gene list of primary AML cells showed significant enrichment in IL1β-stimulated cells for processes 
associated with “inflammation”, “chemokine signaling”, “TNF signaling via p38”, “hypoxia” and “AMLs 
with a NPM1 mutation” (Figure 2C). We confirmed the upregulation of several of the identified genes in 
an independent set of IL1RAP
+
 primary AML samples (Figure 2D and Supplemental Fig 2C). 




population. We sorted 
these populations to elucidate the pathways downstream of IL1RAP (Supplemental Figure 3A). Both of 
them showed similar growth kinetics, clonogenicity in Colony Forming Cell (CFC) assays, and the IL1RAP 
expression remained stable over time (Supplemental Figure 3B-D). As expected, an upregulation of IL8 
upon IL1β stimulation was only observed in IL1RAP+ cells (Figure 3A). The IL1β response was blocked 
with inhibitors against TAK1 and IKK, whereas inhibition of JNK, p38 and MEK/ERK showed less effect 
(Figure 3A). In accordance, K562 IL1RAP
+
 cells showed a strong increase in phosphorylation of p65 upon 
stimulation with IL1β, which could be partially reversed by inhibiting the NFκB-pathway with an IKK 
inhibitor in a dose-dependent manner (Figure 3B-C). These data are in line with previous observations by 
Bosman et al. who studied the TAK1-NFκB axis.17 Next, we transduced K562 IL1RAP+ cells, K562 IL1RAP- 
cells (as negative controls), OCI-AML3 cells, and THP1 cells with shRNAs against IL1RAP and sorted 
transduced cells by GFP positivity (Figure 3D and Supplemental Figure 3E-G). Knockdown of IL1RAP did 
not result in impaired cell proliferation (Figure 3E, Supplemental Figure 3H). We observed reduced 
colony-forming capacity in THP1 cells but not in OCI-AML3 cells (Figure 3F). A trend towards reduced CFC 
capacity upon knockdown of IL1RAP was also observed in primary AML patients #8 and #9 as also 
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observed previously (Figure 3G, Supplemental Figure 3I-J).
28
 Finally, we challenged K562, OCI-AML3 and 
THP1 cells by serum deprivation and stimulated them with IL1β to determine whether cell viability was 
controlled by the IL1-IL1RAP axis under stress conditions. Serum starvation-induced loss of viability, 
however, this was not rescued by addition of IL1β (Figure 3H). 
 
Synergism of the IL1-IL1RAP signaling with other active signaling pathways in AML.  
IL1RAP was recently described to be directly associated with FLT3 (CD135) and c-kit (CD117) 
receptors.
28
 We analyzed co-expression of IL1RAP with signaling receptors including CD135, CD117 and 






 in case of CD34 
expression <1%) by flow cytometry in a cohort of 124 primary AML patients of which four representative 
examples are shown (Figure 4A). Subsequently, patients were defined as single positive, double positive, 
or double negative when at least 50% of the cells resided within either one of the gates (Figure 4A-B). 




, while 4% expressed IL1RAP 









respectively, and we did not identify patients that expressed IL1RAP without any detectable CD117 or 
CD123 (Figure 4B). Expression of IL1RAP, as quantified by flow cytometry (mean fluorescent intensity, 
MFI), correlated significantly with CD123 expression, and to a lesser degree with CD135, but no 
significant correlations were found with CD117 (Figure 4C and Supplemental Figure 4A). These 
observations indicate that IL1RAP signaling can co-occur in cells that are also hardwired for FLT3 ligand 
(FLT3L), Stem Cell Factor (SCF) and/or IL3-induced signal transduction, and in fact might influence those 
pathways as well. In addition, Muto et al showed that MDS HSPC switch from canonical to non-canonical 
NFκB signaling in response to inflammatory signals like IL1β, which might also occur in AML cells.
29
 To 
investigate both hypotheses, we isolated CD34
+ 
cells from AML patients #10-13 and stimulated them 
with IL1β, FLT3L, SCF, IL3, or a combination thereof. Activation of signal transduction pathways was read 
10 
 
out by Western blotting for phosphorylated p65 (p-p65), phosphorylated p100 (p-p100), p52/p100, RelB, 
phosphorylated STAT5 (pSTAT5), phosphorylated p38 (p-p38), and phosphorylated AKT (pAKT), (Figure 
4D-G and Supplemental Figure 4B-E). Figure 4D-E illustrates AML patient #10 that expressed high levels 
of IL1RAP, FLT3, CD117 and CD123 within the CD34
+
 blast compartment. Stimulation with IL1β resulted 
in downstream activation of the canonical NFκB-(p65) and p38 pathways, whereas we observed limited 
activation of non-canonical NFκB (p52/p100, RelB, and p-p100), IL3 activated the STAT5 signaling 
pathway, FLT3L and SCF both activated the PI3K-AKT signaling pathway. Co-stimulation of IL1β with SCF 
resulted in a slightly increased downstream activation of the PI3K-AKT signaling, although no additive 
effects were seen on pSTAT5 or p-p38 (Figure 4D-E). In AML#13, which expressed IL1RAP, CD123 and 
CD117 and low levels of CD135, we observed that IL1β led to activation of p-p38 and a moderate 
activation of only canonical NFκB, IL3 induced pSTAT5, but again the IL3 signaling was not further 
potentiated by co-stimulation with IL1β (Supplemental Figure 4B-C). The third example (AML#11) 
showed increased p-p65 levels upon IL1β stimulation whereas the non-canonical NFκB was active at 
baseline but not further enhanced upon IL1β stimulation as read-out by p52/p100 levels (Figure 4F-G). 
AML#11 responded to FLT3L, SCF and IL3 stimulation, but co-stimulation with IL1β did not further 
enhance activation of any of these signaling pathways (Figure 4F-G). The fourth patient sample (AML#12) 
had limited IL1RAP expression and showed no activation of both canonical and non-canonical NFκB upon 
stimulation with IL1β, no additional activation of the p-p38 signal that was already highly activated at 
baseline, and no effects of co-stimulation with IL1β were seen on IL3-induced pSTAT5 (Supplemental 
Figure 4D-E). Further evaluation of the non-canonical NFκB pathway showed that some primary AML 
patients already have high baseline non-canonical NFκB activity compared to THP1 cells. We did not 
observe differences in baseline non-canonical NFκB activity in K562 IL1RAP
+
 and K562 IL1RAP
-
 cells 
(Supplemental Figure 4F-G). Neither did we observe synergistic effects of IL1β with FLT3L or IL3 in THP1 
cells on downstream phosphorylation of ERK (pERK), cJUN (p-cJUN) and AKT (pAKT) (Supplemental Figure 
11 
 
4H-I, 4K-L). Addition of the anti-IL1RAP monoclonal antibody (α-IL1RAP MAb), that could partly rescue 
IL1-induced upregulation of IL8 and CXCL1, did not alter phosphorylation levels of AKT and cJUN upon 
stimulation with IL1β in combination with FLT3L or IL3 (Supplemental Figure 4J-L). In sum, both the 
canonical NFκB and p38 pathway can be activated by IL1β in primary AML patients whereby downstream 
canonical NFκB-signaling might be correlated to  IL1RAP expression levels. We did not observe synergism 
of IL1β with other signaling molecules including FLT3L, SCF and IL3 on downstream phosphorylation of 
p65, p38, STAT5, AKT, ERK and cJUN. 
 
The IL1-IL1RAP signaling-axis reduces proliferation of normal hematopoietic cells but does not affect 
AML cell growth.  
We showed that IL1RAP is often upregulated in AML cells and that the receptor is functional, 
inducing an inflammatory gene expression signature. However, we found no evidence for a cell-intrinsic 
role for the IL1-IL1RAP axis in controlling cell proliferation or survival under stress conditions. Therefore, 
we wondered whether the inflammatory secretome induced via the IL1-IL1RAP signaling route plays a 
role in inducing an inflammatory BM niche that favors AML cell proliferation over normal hematopoiesis. 
Therefore, IL1RAP-expressing AML CD34
+
 cells were grown in liquid culture conditions or on MSCs, in the 
absence or presence of IL1β. The addition of IL1β had limited impact on the proliferative capacity of 
primary AML CD34
+
 cells, neither when grown in liquid culture conditions nor when grown in co-culture 
with MSCs (Figure 5A). Similarly, IL1β did not affect the proliferation of CB CD34+ cells when grown in 
liquid culture conditions, however, a marked, dose-dependent, reduction in proliferation was noted 
when cultured on MSCs (Figure 5B). From the MSC/AML cultures, the conditioned medium (CM) was 
harvested and transferred to CB-derived or PB-derived CD34
+
 cell cultures to determine the effects on 
proliferation and differentiation (Figure 5C). CM was harvested every time cultures were demi-populated 
12 
 
by taking 1/3 of the volume and transfer it to CB- or PB-derived CD34
+
 cell cultures in a 1:1 ratio (v/v) 
(see supplementary methods for more details)  
The addition of the CM of AML#1 grown in liquid culture conditions did not affect CB CD34
+
 
growth, neither in liquid culture conditions nor when grown on MSCs (Figure 5D-E). Possibly, this relates 
to the high levels of TGFβ, BMPs and angiopoietins that are known to be secreted by stromal cells. These 
factors negatively impact on the cell cycle and can preserve stemness, which would coincide with the 
observation that CD34
+
 cell populations were better maintained under stromal coculture conditions 
(Supplemental figure 5C-D). CM harvested from MSCs, only marginally reduced CB cell growth in liquid 
culture and not when grown on MSCs (Figure 5D-E). Strikingly, the CM harvested from AML#1 grown on 
MSCs negatively impacted on normal CB proliferation, both in liquid cultures and on MSCs, which was 
even further aggravated when the AML cultures were treated with IL1β (Figure 5D-E and Supplemental 
Figure 5A-B). The percentage of DAPI-positive CB cells was slightly increased upon treatment with CM 
from AML cells, compared to the addition of Gartner’s medium (Supplemental Figure 5B).  Similar results 
on cell proliferation and survival were obtained using adult PB CD34
+
 cells that were cultured in presence 
of CM from a different AML (AML#18; Figure 5F and Supplemental Figure 5E). Importantly, the negative 
phenotype could be partially rescued by addition of Anakinra, an FDA-approved inhibitor of the IL1 
receptor, and consequently, the IL1RAP pathway (Figure 5F and Supplemental Figure 5F-H). The CB 
CD34
+
 percentage, but not absolute CD34
+
 cell counts, were increased 3 days after addition of CM of 









 distribution after addition of CM to CB cells grown in liquid culture or on MSCs, 
respectively (data not shown). For a more functional HSPC analysis, we performed a CFC assay with CB 
CD34
+
 cells supplemented with CM of AML-MSC co-cultures. Two high IL1RAP-expressing (AML#9 and 
#19) and two low IL1RAP-expressing (AML#20 and #21) AMLs were grown for 7 days on a stromal layer 





 AML cells (AML#19), but not in the IL1RAP
-
 AML cells (AML #20), and Anakinra abrogated this 
effect (Supplemental Figure 5F). At day 7, CM was harvested and added to the methylcellulose mixture in 
a 1:2 v/v ratio. Only the addition of CM from AMLs with a high IL1RAP expression resulted in a significant 
reduction of colony-forming potential of CB CD34
+
 cells, which was completely reversed by the addition 
of Anakinra (Figure 5G, Supplemental Figure 5J).  
Likely, the stromal cells play an important role in mediating the negative effects of IL1β on the 
proliferation of healthy CD34+ HSPCs. Surprisingly, MSCs expressed high levels of IL1RAP and were 
responsive to IL1β comparable to what was seen for IL1RAP
+
 AML cells (Figure 5H-I). Both the CM of AML 
cells as well as MSCs treated with IL1β affected cell proliferation of healthy HSPCs, which was further 
enhanced when CM from AML + MSC + IL1β was used (Figure 5J, Supplemental Figure 5H). This would 
argue that both the stromal cells as well as AML cells participate in generating an inflammatory 
environment. In addition, two triple co-cultures were performed with MSCs, AML CD34
+
 cells of two 
IL1RAP
+
 AML patients (AML#16 and #22), and CB CD34
+
 cells (Figure 5J-K, Supplemental Figure 5K-L). We 
observed reduced CB proliferation in the presence of AML#16, which was further reduced by the 
addition of IL1β (Figure 5J). CB in co-culture with AML#22 without IL1β did not result in reduced CB 
proliferation, but this was the case when cultured in the presence of IL1β (Supplemental Figure 5K). We 
observed a slight increase of Annexin V
+
 cells at day 16, which might not account fully for the reduced 
normal hematopoiesis.  These data propose a model in which interplay between AML cells and MSCs 
result in an inflammatory secretome that impairs normal hematopoiesis (Figure 5K). This negative 
phenotype of normal hematopoiesis is partly IL1-induced and the addition of exogenous IL1β can 





The fate of normal and leukemic stem cells critically depends on signals arising from the bone marrow 
niche.
30-32
 Many of them initiate signal transduction in target cells by binding to PM receptors. The 
identification and functional analyses of such AML-specific PM proteins will help our understanding of 
leukemia initiation, progression and maintenance. Here, we studied IL1RAP, which  was associated with a 
L-GMP like signature suggesting that cells from IL1RAP
+
 AML patients differ significantly in their origin, 




 High IL1RAP expression in normal 
karyotype AML patients showed worsened overall survival suggesting that indeed these are different 
AML subtypes.
35
 Also at the subclonal level, IL1RAP expression is associated with different biology, as an 
IL1RAP
+
 NRAS-mutated subclone differed significantly from an IL1RAP
-
 WT1-mutated subclone, while 




 NRAS-mutated subclone was strongly 
enriched for L-GMP and inflammatory gene signatures. The connection between dysregulation of the 
Ras-pathway and IL1 signaling was previously investigated in non-small cells lung cancer in the context of 
GATA2 dependency.
36
 Combined, these data indicate that IL1RAP expression can be used to distinguish 
distinct biological characteristics of leukemic clones. 
A recent study indicated that IL1RAP can also co-dimerize with CD117 and CD135 receptors, 
which resulted in an amplification of survival and proliferation signaling in AML.
28
 In our dataset, FLT3 
and CD123, but not CD117 expression, correlated well with IL1RAP expression. Stimulation of these 
receptors with FLT3L, IL3 and SCF showed heterogeneous downstream activation between different 
AMLs but no clear synergism was observed when FLT3, CD123 and CD117 were co-stimulated with IL1β. 
While the hypothesis that IL1RAP receptors can interact with other receptors and thereby affect signal 
transduction is certainly intriguing, further studies are required to resolve these issues.   
We showed that the IL1RAP pathway was functional in primary AML CD34
+
 cells and could be 
activated by IL1β. Various pathways were activated downstream, including canonical NFκB signaling. 
Muto et al. showed that MDS HSPCs could switch to non-canonical NFκB signaling in response to 
15 
 
inflammation, resulting in a competitive advantage over normal HSPCs.
29
 In general, we observed rather 
low levels of proteins involved in active non-canonical NFκB signaling, which was not further increased 
upon stimulation with IL1β suggesting that this switch might be less relevant for AML stem cells. 
Previously, studies showed reduced clonogenicity in AML cell lines as well as reduced engraftment 
capacity upon knockdown or inhibition of IL1RAP using antagonistic antibodies.
28,35
 We also find a 
reduction in CFC frequency upon knockdown of IL1RAP in THP1 cells or primary IL1RAP
+
 AML cells, but 
not in K562 or OCI-AML3 cells. It was also shown that IL1RAP-targeting antibodies resulted in reduced 
cell proliferation, however, we did not observe difference in cell proliferation upon knockdown of 
IL1RAP.
28,35
 Possibly, a reduction in expression is not similar to an antibody-mediated block in signaling. 
Importantly, we did observe an IL1β–induced activation of canonical NFκB signaling in IL1RAP-expressing 
AMLs, but this did not result in NFкB-driven survival under stress conditions such as serum deprivation.  
Intriguingly, the IL1β-induced inflammatory secretome of AML cells grown on MSCs affected 
normal hematopoietic proliferation and HSPC clonogenicity, while AML cells were much less affected. 
This observation was specific for IL1RAP-expressing AML cells that were cultured on stromal cells as CM 
of AML cells and MSCs alone did not affect normal hematopoiesis. We observed only a mild increase in 
DAPI percentage or Annexin V positivity in CB CD34
+
 cells, suggesting that an increase in apoptosis does 
not fully explain the loss of cell growth. Recently, Waclawiczek et al. showed that transcriptionally 
remodeled MSCs due to the presence of AML cells resulted in suppression of HSPCs but did not affect 
their viability.
37
 Along the same lines, Miraki-Moud et al suggested that AML cells do not impair the 
survival of normal HSCs but do inhibit their differentiation, from which HSCs can recover once removed 
from the leukemic environment.
38
 Single cell sequencing studies of the mouse bone marrow provided a 
very detailed description of the cellular heterogeneity within the BM niche, which was remodeled upon 
stress or MLL-AF9 leukemia engraftment.
39,40
 This remodeling affected function and maturation of BM 





 Similarly, studies showed BM remodeling  via exosome secretion, TGF-β, Notch and 
inflammatory signals.
41,42
 Together, these findings suggest that leukemic cells can impact on normal 
hematopoiesis in multiple ways. Likely, there are more proteins secreted by AMLs and/or MSCs that also 
influence normal hematopoietic proliferation, as Anakinra could not fully rescue the negative phenotype. 
For example, Carter and colleagues showed that IL1β can result in a Cox2-dependent secretion of 
prostaglandin E2 (PGE2) by MSCs, which ultimately resulted in β-catenin-mediated augmented 
chemotherapy resistance in AML cells.
43
 Besides inflammatory factors, GATA2 was also upregulated ~2.6 
fold in AML cells upon IL1β stimulation. p38-dependent GATA2 activation has been associated with poor 
overall survival and increased transcriptional activation of IL1β and CXCL2.
44,45
 We hypothesize that this 
p38-dependent activation of GATA2 is part of a positive feedback loop in IL1RAP-expressing AMLs that 
results in an inflammatory niche.  
The formation of an inflammatory niche possibly plays a role in the early stages of leukemia 
development as well. It has been shown that hematopoietic clones harboring a pre-leukemia mutation in 
Tet methylcytosine dioxygenase 2 (TET2) can outgrow non-mutated clones after inflammatory stress, 
which in turn might be aggravated by the fact that TET2 knockout mice show increased levels of 
inflammatory proteins including IL1b, IL-6 and chemokines including Cxcl1-3 and Pf4.
46,47
 Upon ageing, 
the BM niche changes and becomes more senescent and as a result, via a senescent-associated secretory 
phenotype (SASP), more inflammatory.
48-50
 Although the data are limited, it is enticing to consider that 
an inflammatory BM niche might accelerate clonal expansion and that the IL1-IL1RAP signaling axis plays 
an important role already in early stages of leukemic initiation.  
 Overall, our study contributes to the understanding of the role that plasma membrane receptors 
play in the leukemic BM niche. Such insights might aid further development of therapies aimed at 
specifically targeting factors that are essential for leukemogenesis. Inhibition of the IL1-IL1RAP signaling 
17 
 
axis might be a good therapeutic approach to reduce inflammation in the BM niche and thereby promote 
normal hematopoietic recovery over AML proliferation after chemotherapy. 
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Figure 1. High IL1RAP PM protein expression in AML is associated with a L-GMP signature. (A) 
Immunofluorescent staining and expression measured by flow cytometry (red histogram) of IL1RAP in 
multiple AML cell lines and one primary AML patient. The grey histogram indicates the unstained control. 
(B-C). GO analysis (C) and GSEA (D) on a ranked gene list based on label-free quantitative protein 
expression in 42 primary AML patient samples.
7
 Genes were ranked based on Pearson correlation with 
IL1RAP protein expression. Normalized enrichment score (NES) and false discovery rate (FDR) were used 
to determine significance. * p<0.05, *** p<0.001. 
 
Figure 2. IL1-induced IL1RAP signaling is associated with an inflammatory secretome. 
 (A) Transcriptome analysis of genes 2-fold upregulated in one primary AML patient and two AML cell 
lines upon stimulation with IL1β. (B) GO-analysis on 331 genes that were 2-fold upregulated in at least 
two out of three groups (THP1, K562 and AML#1). (C) GSEA-analysis on a ranked gene list of AML patient 
#1. Genes were ranked from upregulated to downregulated upon stimulation with IL1β. NES and FDR 
were used to determine significance. (D) qRT-PCR analysis of five primary AML patient samples ± IL1β 
stimulation. Bars indicate mean ± SD of biological triplicates. Statistical analysis was performed by a one-
tailed Student´s t.test. * p<0.05; ** p<0.01; *** p<0.001. 
 
Figure 3. IL1-IL1RAP mediated activation of the NFκB signaling does not rescue proliferation under 
stress conditions, but IL1RAP knockdown results in reduced colony-forming capacity. (A) qRT-PCR 




 cells treated with TAK1, NFκB, JNK, p38 and MEK inhibitors and 





 treated with or without IL1β and/or IKK inhibitor (IKK inh). (C) Quantification of 
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 cells transduced with shRNA’s including a non-targeting control (scr) and 
shRNA’s targeting IL1RAP (shI and shII). Bars indicate mean ± SD of technical triplicates. (E) Growth 




 cells (n=3) ± knockdown of IL1RAP. (F) CFC output of OCI-AML3 and 
THP1 ± knockdown of IL1RAP. Bars indicate mean ± SD of technical duplicates. (G) CFC output of AML#8 
and #9 ± knockdown of IL1RAP. Bars indicate mean ± SD of technical duplicates. (H) Growth curves after 
serum depletion of K562, OCI-AML3 and THP1 cells (n=3) ±IL1β. Statistical analysis in all panels was 
performed using a Student’s t.test. * p<0.05; ** p<0.01; *** p<0.001. 
 
Figure 4. Synergism of the IL1-IL1RAP signaling with other active signaling pathways in AML. (A) Gating 
strategy of co-expressing IL1RAP, CD135, CD123 and CD117 measured by flow cytometry within four 
representative primary AML patients. (B) Pie-chart showing co-expression of IL1RAP with CD135, CD123 
and CD117 in blasts of 124 primary AML patients. At least 50% of the total amount of cells in a specific 
group was used as a cut-off to include a patient in a certain group; otherwise, patients were called 
“unclassified”. (C) Pearson correlation of IL1RAP with CD135, CD123 and CD117 based on MFI (n=124). 
(D) Western blot of primary patient CD34
+
 blasts positive for IL1RAP, CD135, CD117 and CD123. Cells 
were stimulated with IL1β, FLT3L, SCF, IL3 or a combination of these cytokines. (E) Quantification of 
Western blot in panel D. p-p65 was normalized to total H3, pSTAT5 and p-p38 were normalized to β-
ACTIN and pAKT was normalized to AKT. (F) Western blot of primary patient CD34
+
 blasts with low 
IL1RAP and CD135 expressing but positive for CD117 and CD123. Cells were stimulated with IL1β, FLT3L, 
SCF, IL3 or a combination of these cytokines. (G) Quantification of Western blot in panel F. p-p65 was 





Figure 5. The IL1-IL1RAP signaling pathway affects normal hematopoiesis but not AML cell growth in 
the context of human MSCs. (A) Growth curve of AML#1 CD34
+
 cells in liquid culture (left) and on a 
stromal layer of MSCs (right) ±IL1β in different concentrations. The arrow indicates from whereon IL1β 
has been added. (B) Growth curve of CB CD34
+
 cells in liquid culture (left) and on a stromal layer of MSCs 
(right) ±IL1β in different concentrations. The arrow indicates from whereon IL1β has been added. (C) 
Schematic overview of experimental setup of co-cultures and conditioned medium (CM) transferring. (D-
E) Growth curve (left) and cumulative cell number on day 14 (right) of CB CD34
+
 cells in liquid (D) and on 
a stromal layer of MSCs (E) with the addition of CM from a MSC culture (CM MSC), AML#1 CD34
+
 liquid 
culture (CM AML), AML#1 CD34
+
 MSC co-culture (CM MSC + AML), and AML#1 CD34
+
 MSC co-culture 
with the addition of 10ng/mL IL1β (CM MSC + AML + IL1β). CM was added at day 4 (arrow) and every 
following demi-population. (F) Growth curve (left) and cumulative cell number on day 21 (right) of CD34
+
 
PBSCs grown on MSCs with the CM from AML#18 (co-)cultures. Treatment conditions were similar to the 
once described in Figure legend 5D-E, adding one condition including AML CD34
+
 co-culture with the 
addition of 10ng/mL IL1β and 500 ng/mL Anakinra (CM MSC + AML + IL1β + Anakinra). CM was added at 
day 0 and at every following demi-population. (G) CFC assay of CB CD34
+
 treated with CM of IL1RAP
high
 
AMLs (AML#9 and AML#19) and IL1RAP
low
 AMLs (AML#20 and AML#21), which were cultured for 7 days 
on a MSC stromal-layer in the presence or absence of IL1β and Anakinra, before CM was harvested. Data 
of two biological duplicates are shown relative to the untreated condition. (H) IL1RAP expression on 
MSCs measured by flow cytometry. (I) qRT-PCR of MSCs stimulated with and without IL1β. Statistical 
analysis was performed using a Student’s t test. (J) Cumulative cell number on day 21 of CD34
+
 PBSCs 
grown on MSCs (experimental setup identical to panel F) including conditions AML + IL1β and MSC + 
IL1β. Gartner’s and CM MSC + AML + IL1β (identical to panel F) has been added for direct comparison. (K) 
Growth curve (left) and cumulative cell number on day 11 (right) of CB CD34
+
 cells in triple co-culture 
with MSCs and AML#16 CD34
+
 cells ±IL1β (L) Percentage of CB cells in triple co-culture with MSCs and 
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AML#22 ±IL1β at day 4. (M) Schematic model how AML cells might impact on normal hematopoiesis in 
the BM niche, in part via the IL1-IL1RAP axis. Statistical analysis in all panels was performed using a 
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Neonatal cord blood (CB) was harvested from healthy full-term pregnancy placentas, healthy 
mobilized peripheral blood stem cells (PBSCs) were obtained from left overs of transplant material, 
normal bone marrow (NBM) was obtained after hip surgery of healthy individuals. Cells from acute 
myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients were obtained from bone 
marrow (BM) or peripheral blood (PB) at diagnosis. Primary mesenchymal stromal cells (MSCs) were 
retrieved from a healthy donor that underwent hip surgery. MSCs were expanded in αMEM with 
200mM glutamine (Lonza), 10Units/mL heparin, 5% human platelet lysate (Sanquin) and 1% p/s and 
frozen at low passage until further use. Mononuclear cells (MNCs) were isolated using a ficoll gradient 
separation (LymphoprepTM) and either freshly used or frozen in liquid nitrogen. Cryopreserved MNCs 
of AML patients and mobilized PB were thawed, resuspended in new born calf serum (NCS) 
supplemented with DNase I (20Units/mL), 4µM MgSO4 and heparin (5Units/mL) and incubated on 
37˚C for 15 min. CD34+ cells of CB, mobilized PB and AML MNCs were isolated on the autoMACS Pro 
Separator using a magnetically activated cell-sorting progenitor kit (Miltenyi Biotech). All healthy 
individuals and AML patients gave an informed consent in accordance with the Declaration of Helsinki 
at the University Medical Centre Groningen (UMCG) and Martini Hospital Groningen, the Netherlands. 
All protocols were approved by the Medical Ethical Committee of the UMCG.  
 
Cell (co-/triple-)cultures 
Leukemic human cell lines were cultured in RPMI 1640 medium with 200mM glutamine (Lonza) 
supplemented with 10% fetal calf serum (FCS) (Lonza) and 1% penicillin-streptomycin (p/s) (PAA 
laboratories), at 37°C. In case of serum depletion (Figure 3H), cells were treated with 10%, 1% and 
0.5% FCS ± 10ng/mL IL1β (Sigma-Aldrich). Fresh medium and IL1β was added after each demi-
population. For co-culture experiments, cryopreserved MSCs of the same donor were thawed, 
resuspended in Gartner’s medium consisting of αMEM with 200mM glutamine supplemented with 
12.5% FCS, 12.5% horse serum (Invitrogen), 1% p/s, 57,2µM β-mercaptoethanol and 1µM 
hydrocortisone (both Sigma-Aldrich). MSCs were plated in 0.1% gelatin coated 96-wells plates and 
grown confluent. Subsequently, 1x105 AML CD34+ cells or between 5x103-15x103 PBSC/CB CD34+ cells 
were plated into Gartner’s medium with the addition of 20ng/mL granulocyte colony-stimulating 
factor (G-CSF), Nplate and IL3. Inhibition of the IL1-signaling pathway was established by the addition 
of 500ng/mL Anakinra (Swedish Orphan Biovitrum BVBA). MSC/AML/CB/PBSC (co-)cultures were 
grown at 37˚C and 5% CO2 and demi-populated every 3-5 days, replacing 50% of the volume with fresh 
Gartner’s medium or conditioned medium (CM). CM was added in a 1:1 ratio (v/v) to CB CD34+ 
cultures after 4 days and subsequently every time they were demi-populated (t=7, t=10, and t=14) 
(Figure 5C-E). In case of PBSC CD34+ cultures, CM was added at day 0 and every following demi-
population (t=4, t=11, t=15, t=18) (Figure 5F, and 5J). In case of triple co-cultures, CB CD34+ cells were 
lentivirally transduced with a pLKO eGFP vector in order to distinguish them from AML cells. CB 
CD34+GFP+ cells were plated on a confluent layer of MSCs in a 1:15 – 1:20 ratio with AML CD34+ cells 
and demi-populated every 3-5 days replacing 50% of the volume with fresh Gartner’s medium. All 
cultures were performed in triplicate. Suspension cells were retrieved by shaking on a plate shaker, 
stained with CD34, CD38, CD45, AnnexinV, and DAPI (Thermo Scientific) and analyzed on the 
MacsQuant Analyzer 10 (Mylteni) or CytoFLEX (Beckman Coulter) flow cytometer. 
 
Flow Cytometry 
Cryopreserved MNCs of AML and MDS patients and NBM samples were thawed as described in the 
“patient samples” section. In general, for flow cytometry analysis and cell sorting, cells were treated 
with human FcR blocking reagent (Miltenyi Biotech) prior to antibody staining. Subsequently, cells 
were incubated with the appropriate antibody cocktail and incubated at 4˚C for 30 min. Immediately 
before analysis, DAPI (Thermo Scientific) was added as viability stain. Flow cytometry analysis in the 
diagnostic research lab, as shown in Figure 4A-B, Supplemental Figure 1A-B, and Supplemental Figure 
4A, was performed according to the Euroflow protocol 1. Here, freshly obtained whole BM aspirated 
samples were used. After ammonia lysis of erythrocytes, the isolated BM cells were FcR blocked with 
50mg/mL human IgG (Sanquin) and incubated with different antibodies. After incubation, the cells 
were fixed with FACS lysing solution (BD Biosciences) and washed twice in PBS before flow cytometric 
measurements. Fluorescence was measured on the MacsQuant Analyzer 10 (Miltenyi Biotech) or in 
case of the routine diagnostics on the FACSCanto II TM flow cytometer (BD Biosciences). Cell sorting 
was performed on a MoFlo XDP (Beckman Coulter). Data were analyzed using Flow Jo (Tree Star, Inc) 
in case of Supplemental Figure 1A-B. Co-expression of IL1RAP with FLT3, CD117 and CD123 in case of 
Figure 4A-B, and Supplemental Figure 4A was analyzed with InfinicytTM (Cytognos) in order to merge 
expression on the basis of a common backbone followed by analysis in Flow Jo (Tree Star, Inc). 
Antibodies used in this study: CD34 (581), CD45 (HI30), FLT3 (4G8), CD38 (HIT2), AnnexinV 550475 (all 
BD Biosciences), IL1RAP (#89412) (R&D), CD123 (6H6) (Biolegend), CD34 (581) (Thermo Scientific), and 
CD117 (104D2D1) (Beckman Coulter).  
 
Colony-forming-cell (CFC) assay 
AML#9, #19-21 were cultured on a stromal layer of MSCs and treated with or without IL1β and 
Anakinra for 7 days. 900µL CM was harvested and mixed with 1600µL methylcellulose (Stem Cell 
Technologies), and supplemented with 20ng/mL IL3, IL6, SCF, G-CSF, and TPO.  CB CD34+ cells were 
sorted directly into the CFC-mixture and plated in two cell culture dishes as technical duplicate. 
Colonies were scored after 2 weeks of incubation at 37°C. 
 
Lentiviral transfection 
HEK 293T cells were transfected with 3µg of the pLKO eGFP construct, containing short hairpins 
against IL1RAP sh1: 5’-TGGCCTTACTCTGATCTGGTATTGGACTA-3’ , sh2: 5’-
CGGGCATTAATTGATTTCCTACTATATTC-3’2 or scrambled control 5’-TTCTCCGAACGTGTCACGTT-3’, 
together with 3µg of the packaging construct pCMV-dR8.91 (Delta 8.9) containing gag, pol and rev 
genes, 0,7µg of glycoprotein VSV-G expressing envelope plasmid and 21µl Fugene transfection reagent 
(Roche). In case of AMLs, prior to transduction the virus was concentrated 10 times and 24 wells plates 
were coated with retronectin. 0.75x106-1x106 AML cells per well were transduced in 400 µL of 
Gartner's medium supplemented with 20ng/ml G-CSF, N-plate, and IL3, and 8µg/ml polybrene (Sigma-
Aldrich) with 200µL of the virus. After 24 hour (hr), the cells were washed 3 times with PBS + 2% FCS 
and a second round of transduction (24 hr) was performed. Cells were washed 3 times and plated on 
mouse stromal 5 (MS5) cells in Gartner's medium supplemented with 20ng/ml G-CSF, N-plate, and IL3 
until sorting.  Viral particles were collected in αMEM and stored at -80°C until further use. For 
transduction, AML cell lines were transduced in 2 rounds with 1:1 ratio virus to medium in the 
presence of 8µg/mL Polybrene. Cells were washed 3 times with PBS + 2% FSC and sorted for GFP+DAPI- 
on a MoFlow Astrios cell sorter (Beckman Coulter). 
 
Immunofluorescent microscopy 
5x104 cells were spun down on slides with a cytospin and immediately fixated in 4% paraformaldehyde 
(PFA), permeabilized with PBS + 0,1% Triton X-100 and washed once with PBS+ (blocking solution 
containing 0,5% bovine serum albumin (BSA) and 0,15% glycine). Slides were incubated with primary 
antibodies Rabbit anti-IL1RAP (Thermo Scientific) in a moist environment at room temperature, rinsed 
with PBS + 0,1% Triton X-100 and PBS+ and incubated with secondary antibodies FITC-Goat anti-Rabbit 
(Life Technologies). At the final step, DAPI solution (Thermo Scientific) was added, cells were washed 
with PBS and preserved in the mounting medium (Vector Laboratories). Images were taken with a 
DM6000B fluorescent microscope (Leica). 
 
Western blotting 
For the detection of phosphorylated proteins, 5x104 primary AML CD34+ cells were serum-starved for 
1 hr, stimulated with 20 or 100ng/mL IL1β for 10 min, spun down in a pre-cooled centrifuge at 4°C and 
directly boiled in Laemmli-SDS-PAGE sample buffer. In case of K562 IL1RAP+/- cells (Figure 3B), cells 
were incubated with or without 2µM or 10µM IKK inhibitor (BMS-345541, Sigma Aldrich) for 4 hr, and 
subsequently stimulated with 20ng/mL IL1β for 15 minutes. Evaluation of non-canonical NFκB in 
AML#14-17 was performed on the mononuclear cell fraction. For co-stimulation analysis, AML cells 
were stimulated for 10 min either alone with 50ng/mL FLT3L, SCF or IL3 or in combination with 
20ng/mL IL1β. In case of co-stimulation analysis in THP1 cells, 5x104 cells were serum-starved for 3 hr 
and subsequently stimulated for 10 min with 10ng/mL or 50ng/mL IL1β alone or in combination with 
either 50ng/mL FLT3L or 50ng/mL IL3. IL1-signaling was blocked using 10µg/mL anti-IL1RAP MAb 
(R&D) for 24 hr prior to stimulation. Samples were loaded onto a Mini-PROTEAN® TGX™ Precast 
Protein Gel (Bio-Rad) and run in electrophoresis buffer (25mM, 152mM glycine, 0.07% SDS). The 
PageRuler Plus Prestained Protein Ladder (Thermo Scientific) was used to determine protein size. 
Subsequently, the gel was blotted onto a methanol activated PVDF FL-membrane (Immobilion) using 
a Trans-Blot Turbo™ Blotting System (Bio-Rad) according to the manufacturer’s protocol. The 
membrane was blocked with Odyssey Blocking Buffer in PBS (Li-Cor), followed by blocking in milk in 
case of p52/p100, and incubated overnight with primary antibodies including phospho-p38 
Thr180/Tyr182, phospho-AKT Ser473, phospho-ERK 1/2 T202/Y204 (CST), p-cJUN S73(CST), p-p65 
Ser536, p-p100 Ser866/870, p100/p52 (#4882), RelB (#4922) (all Cell Signaling Technology, CST), and 
phospho-STAT5 pY694 (BD Biosciences). Total AKT (pan) (CST), total H3 (CST) and β-ACTIN (Santa Cruz) 
were used as loading controls. Blots were washed with TBST (TBS with 0,1% Tween 20) and incubated 
for 2 hr with secondary antibodies including anti-mouse Alexa Fluor 800 and anti-rabbit Alexa Fluor 
680 (Invitrogen). The membranes were visualized on the Odyssey CLx Near-Infrared Fluorescence 
Imaging device (Li-Cor) and analyzed with Image Studio Lite 5.2 software. 
 
Transcriptome analysis 
2x105 K562, THP1 and AML CD34+ cells were stimulated in 10ng/mL IL1β (Sigma-Aldrich) for 1 hr. Cells 
were harvested and RNA was isolated using the RNeasy mini kit (Qiagen) according to the 
manufacturer’s protocol. Genome-wide expression analysis was performed on Illumina (Illumina, Inc) 
BeadChip Arrays (Illumina Human HT-12 v4 Expression Beadchips). 0.75µg of cRNA combined was used 
in labelling reactions and hybridization with the arrays according to the manufacturer’s instructions. 
Data was analyzed using GenomeStudio V2011.1 Gene Expression Module v1.9.0 (Illumina, Inc.) and 
Genespring (Agilent). A quantile log2 normalization of the data was performed. Gene ontology (GO) 
analysis and gene set enrichment analysis (GSEA) was performed on a ranked gene list using Gorilla 
and GSEA 4.0.3 software, respectively 3,4. In case of IL1RAPhigh and IL1RAPlow protein expression, 
proteins annotated in at least 10 AML samples were ranked on Pearson correlation coefficient with 
IL1RAP expression (n=42). GSEA was performed with respect to MsigDB C2 and C5 gene sets (version 
7) or gene sets generated from selected publications as shown in the relevant figures. 
 
qRT-PCR 
2x105 primary AML CD34+ cells, human MSCs, K562 IL1RAP+/- or THP1 cells were incubated with 
10ng/mL IL1β for 1 hr. IL1-signaling was blocked using 10µg/mL anti-IL1RAP MAb (R&D) or 500ng/mL 
Anakinra for 24 hr prior to stimulation. RNA was isolated using the RNeasy Mini Kit (QIAGEN) according 
to the manufacturer’s protocol. cDNA was synthesized with iScript cDNA Synthesis Kit (Bio-Rad) and 
qRT-PCR was performed using SsoAdvanced™ Universal SYBR Green Supermix on the CFX Connect 
Real-Time instrument (Bio-Rad). Expression of the ribosomal protein like (RPL) 27 gene was used to 
calculate relative expression levels. In case of inhibitory experiment in Figure 3A, cells were pre-
treated with TAK1 inhibitor (100nM 5z-7-oxozeaenol), NFκB inhibitor (2µM BMS-345541), P38 
inhibitor (5µM SB203580) or MEK/ERK inhibitor (10µM U0126) (all Sigma-Aldrich) for 2 hr prior to 
stimulation with 10ng/mL IL1β for 1 hr. 
 
Statistical analysis 
Data of growth curves and qRT-PCR are presented as mean ± SD. Significance was determined by 
either a Kruskal-Wallis test or Student’s t.test using Graphpad Prism software as indicated in the 
figure legends. p values are indicated in the figure legends. FDR q-values and NES scores were used 
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